Evidence map›Paper›PMID 35875077›Full record

ReviewFrontiers in oncology2022

Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Jie Zhao, Jinhui Guo, Yanan Wang, Qiancheng Ma, Yu Shi, Feng Cheng, Qiliang Lu, Wen Fu, Guangxiong Ouyang, Ji Zhang and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Research progress of DUB enzyme in breast cancer.Clinical and experimental medicine · 2025
    Review
  9. Review
  10. Review
  11. The Knockdown of USP34 Inhibits the Progression of Hepatocellular Carcinoma by Accelerating c-Myc Degradation.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jie ZhaoCollege of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China.
Jinhui GuoQingdao Medical College, Qingdao University, Qingdao, China.
Yanan WangCollege of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China.
Qiancheng MaCollege of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China.
Yu ShiCollege of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China.
Feng ChengCollege of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China.
Qiliang LuQingdao Medical College, Qingdao University, Qingdao, China.
Wen FuQingdao Medical College, Qingdao University, Qingdao, China.
Guangxiong OuyangQingdao Medical College, Qingdao University, Qingdao, China.
Ji ZhangCollege of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, China.
Qiuran XuLaboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
Xiaoge HuDepartment of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College Hangzhou, China.
Zhejiang University of Technology · CNQingdao University · CNHangzhou Medical College · CNZhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to GLOBOCAN 2021 cancer incidence and mortality statistics compiled by the International Agency for Research on Cancer, hepatocellular carcinoma (HCC) is the most common malignancy in the human liver and one of the leading causes of cancer death worldwide. Although there have been great advances in the treatment of HCC, such as regofenib, sorafenib, and lomvatinib, which have been developed and approved for the clinical treatment of advanced or metastatic HCC. However, they only prolong survival by a few months, and patients with advanced liver cancer are susceptible to tumor invasion metastasis and drug resistance. Ubiquitination modification is a type of post-translational modification of proteins. It can affect the physiological activity of cells by regulating the localization, stability and activity of proteins, such as: gene transcription, DNA damage signaling and other pathways. The reversible process of ubiquitination is called de-ubiquitination: it is the process of re-releasing ubiquitinated substrates with the participation of de-ubiquitinases (DUBs) and other active substances. There is growing evidence that many dysregulations of DUBs are associated with tumorigenesis. Although dysregulation of deuquitinase function is often found in HCC and other cancers, The mechanisms of action of many DUBs in HCC have not been elucidated. In this review, we focused on several deubiquitinases (DUBs) associated with hepatocellular carcinoma, including their structure, function, and relationship to hepatocellular carcinoma. hepatocellular carcinoma was highlighted, as well as the latest research reports. Among them, we focus on the USP family and OTU family which are more studied in the HCC. In addition, we discussed the prospects and significance of targeting DUBs as a new strategy for the treatment of hepatocellular carcinoma. It also briefly summarizes the research progress of some DUB-related small molecule inhibitors and their clinical application significance as a treatment for HCC in the future.

Indexed as

deubiquitinating enzymeshepatocellular carcinomainhibitorsstructuretargetedubiquitin

Identifiers

PMID35875077
PMCPMC9303014
OpenAlexW4283585111

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.